Zero-Tolerance Statement on Corruption and Influence Peddling

Preventing and detecting corruption is a priority for both Sartorius Group and its subgroup Sartorius Stedim Biotech. The Executive Board of Sartorius AG and the Board of Directors of Sartorius Stedim Biotech S.A., together with senior management, are committed to conducting business with integrity, fairness, and respect for the law. We have zero tolerance for any unethical behavior involving corruption or influence peddling, and we expect the same commitment throughout our organization.

Our commitment is rooted in our values; our actions are guided by the risks we face. Under the shared responsibility of the Executive Board of Sartorius AG and the Board of Directors of Sartorius Stedim Biotech S.A., Sartorius regularly identifies and assesses corruption and influence-peddling risks arising from its business activities, global presence and interactions with customers, suppliers, business partners and public authorities. These assessments help us understand where risks are most relevant and ensure that our prevention, detection, and remediation efforts focus on where they can have the greatest impact.
Particular attention is given to risks relating to the misuse of marketing, hospitality, sponsorship or other benefits to improperly influence customers or other external decision makers, including in tender processes, and to improper payments or other advantages provided to representatives of public authorities.

No benefit is worth compromising our integrity. Corruption and influence peddling are never acceptable, regardless of the circumstances or expected business outcome.
This applies to direct and indirect as well as active and passive conduct in all interactions with public officials, customers, suppliers, business partners, and other third parties.
Bribery, kickbacks, facilitation payments, improper gifts or hospitality, inappropriate sponsorships or donations, and any attempt to improperly influence a decision are inconsistent with Sartorius' values and have no place in the way we conduct business.
This also includes influence peddling: No one may offer, promise, give, request or accept an undue advantage in exchange for using personal relationships, special access or alleged influence over a public official or decision maker.
Sartorius earns customer trust, business opportunities and regulatory outcomes through integrity, expertise and performance, never through improper advantages or influence.

Our commitment applies to everyone acting for Sartorius. This statement applies to all directors, officers, managers, and employees across the Sartorius Group and its subgroup Sartorius Stedim Biotech. The Executive Board of Sartorius AG and the Board of Directors of Sartorius Stedim Biotech S.A., together with senior management, expect all employees to act honestly, avoid conflicts of interest, exercise good judgment, and comply with applicable laws and company policies. We also expect business partners, contractors, consultants, intermediaries, and other third parties acting on our behalf to uphold the same standards.

When in doubt, ask. When concerned, speak up. If there is any doubt about whether an action is appropriate, guidance should be sought before proceeding. Managers, Legal and Compliance teams, and other designated functions are available to provide support. The Executive Board of Sartorius AG and the Board of Directors of Sartorius Stedim Biotech S.A., together with senior management, encourage employees to use the established reporting channels whenever they have concerns about potential misconduct or violations of anti-corruption requirements.

Speaking up must never lead to retaliation. Sartorius does not tolerate retaliation against anyone who speaks up in good faith or participates in an investigation. The Executive Board of Sartorius AG and the Board of Directors of Sartorius Stedim Biotech S.A., together with senior management, are committed to fostering a culture in which employees feel comfortable raising concerns. Reports are handled responsibly and in accordance with applicable confidentiality, data protection, and procedural requirements.

Violations have consequences. Corruption can harm Sartorius, our stakeholders, and the individuals involved. Misconduct is addressed appropriately and consistently, and may result in disciplinary, contractual, commercial or legal consequences in accordance with applicable laws and company requirements.

Turning commitment into daily practice. The Executive Board of Sartorius AG and the Board of Directors of Sartorius Stedim Biotech S.A., together with senior management, ensure that the resources needed to prevent, detect and address corruption risks are in place and effective across day-to-day business.
This commitment is embedded in Sartorius' broader anti-corruption framework, including the Code of Conduct, Anti-Corruption Code, risk-based training, risk assessments, third-party due diligence, reporting channels, internal controls, monitoring and remediation measures.

Endorsed by leadership. This statement has been adopted by the Executive Board of Sartorius AG and the Board of Directors of Sartorius Stedim Biotech S.A., endorsed by senior management, reflecting their shared responsibility for promoting a culture of integrity and compliance across Sartorius.

This statement will be communicated to employees and relevant business partners. It will be reviewed and updated as needed to remain aligned with the risk profiles, legal requirements, and anti-corruption frameworks of both Sartorius Group and its subgroup Sartorius Stedim Biotech.

Last updated: October 2026 | Version 1.0